Acadia Pharmaceuticals is a company dedicated to innovation in neurological and rare disease therapies. Our portfolio includes the first FDA‑approved treatments for Parkinson’s disease psychosis and Rett syndrome, and we are developing additional programs in Alzheimer’s disease